This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Northwestern Medicine Researchers Study New Heart Valve That Doesn't Require Open-heart Surgery

Bluhm Cardiovascular Institute enrolls first patient in SALUS trial at Northwestern for movable, non-metallic heart valve

CHICAGO, Oct. 9, 2013 /PRNewswire-USNewswire/ -- Northwestern's Bluhm Cardiovascular Institute has enrolled its first participant in SALUS, a clinical trial studying the effectiveness of a prosthetic aortic heart valve that can be placed without open-heart surgery. The heart valve under study, the Direct Flow Medical ® Transcathether Aortic Valve System manufactured by Direct Flow Medical, Inc., is a non-metallic, investigational device specifically designed to be placed inside the heart using a catheter that is inserted through a blood vessel in the groin and then navigated into the aorta to the heart. The study valve is also designed to have the unique ability to be repositioned or even replaced with a different size after the valve's initial placement to achieve a better fit if one is needed.

SALUS is the first U.S. clinical trial of the Direct Flow Medical Transcathether Aortic Valve System, and will seek to evaluate how well the test valve can be delivered and its effectiveness once it is in use. Northwestern's enrollment is the first in Illinois and the fourth institute in the country to enroll subjects.

"Aortic stenosis is a condition that commonly affects older individuals. The leaflets of the aortic valve become thick and calcified and ultimately can limit the ability of blood from being pumped out of the heart," said James D. Flaherty, MD, Northwestern Medicine cardiologist and Northwestern's principal investigator for SALUS. "When the narrowing becomes severe, patients develop symptoms such as shortness of breath, fatigue, lightheadedness and chest pain. If uncorrected, their life expectancy is also significantly shortened."

Open-heart surgery has been the gold standard treatment for aortic stenosis since the 1960's.  However, many patients are considered high-risk or inoperable for traditional heart surgery.  Transcatheter Aortic Valve Replacement (TAVR) is a technique to insert a new aortic valve through catheters instead of open heart surgery. The only transcatheter heart valve that is commercially available in the United States requires larger catheters than the study valve, sits within a metal ring, and cannot be repositioned or replaced once it is released from the catheter.

"Aortic valve replacement is a life saving procedure for patients with severe symptomatic aortic stenosis. TAVR, which is done without the need of a cardiopulmonary bypass machine, may also prove to be life saving in patients who are not eligible for cardiac surgery," said Flaherty, who is also an Associate Professor of Medicine in Interventional Cardiology at the Feinberg School of Medicine of Northwestern University. "This study valve is inserted through smaller catheters and its unique design allows it to be repositioned or replaced until the Heart Team is satisfied that it is in the optimal position. It is also expected that this design will prove to cut down or even eliminate any leaking, called aortic regurgitation, around the implanted valve."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs